# US 2015/0105440 A1 · Antisense modulation of apolipoprotein b expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105440 A1
- Document ID: US20150105440A1
- Status: Published application
- Kind: A1
- Application number: 14/286,621
- Filed: 2014-05-23
- Published: 2015-04-16
- Earliest claimed: 2001-08-01
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Rosanne M. CROOKE; Mark J. GRAHAM
- Web page: https://patentgrep.com/patent/US20150105440A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/11: Antisense
- C12N 2310/314: Phosphoramidates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

## Claims

### Claim 1

A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding apolipoprotein B.

### Claim 2 (depends on 1)

The compound of claim 1 which is an antisense oligonucleotide.

### Claim 3 (depends on 2)

The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 17, 18, 19, 20, 21, 23, 24, 25, 27, 28, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 61, 62, 63, 66, 67, 69, 71, 73, 74, 75, 76, 78, 79, 81, 82, 83, 84, 86, 87, 88, 90, 93, 96, 101, 101, 102, 103, 105, 109, 111, 111, 114, 115, 116, 117, 118, 119, 120, 121 or 122.

### Claim 4 (depends on 2)

The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar moiety, or at least one modified nucleobase.

### Claim 5 (depends on 4)

The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage; (ii) the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety; or (iii) the modified nucleobase is a 5-methylcytosine.

### Claim at position 6

-9. (canceled)

### Claim 10 (depends on 2)

The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

### Claim 11

A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding apolipoprotein B.

### Claim at position 9

-14. (canceled)

### Claim 15 (depends on 1)

A method of inhibiting the expression of apolipoprotein B in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of apolipoprotein B is inhibited.

### Claim 16 (depends on 1)

A method of treating an animal having a disease or condition associated with apolipoprotein B comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of apolipoprotein B is inhibited.

### Claim 17 (depends on 16)

The method of claim 16 wherein the condition involves abnormal lipid metabolism the condition involves abnormal cholesterol metabolism; or the condition is atherosclerosis.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The compound of claim 1 targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits the expression of the long form of a nucleic acid molecule encoding apolipoprotein B, ApoB-100.

### Claim 21 (depends on 16)

The method of claim 16 wherein the condition is an abnormal metabolic condition, hyperlipidemia, diabetes, Type 2 diabetes, obesity, atherosclerosis, or a cardiovascular disease.

### Claim at position 17

-27. (canceled)

### Claim 28 (depends on 1)

A method of modulating glucose levels in an animal comprising administering to said animal the compound of claim 1.

### Claim at position 19

-32. (canceled)

### Claim 33 (depends on 1)

A method of preventing or delaying the onset of a disease or condition associated with apolipoprotein B in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The method of claim 33 wherein the condition is an abnormal metabolic condition, hyperlipidemia, diabetes, Type 2 diabetes, obesity, atherosclerosis, or wherein the condition involves abnormal lipid metabolism or abnormal cholesterol metabolism.

### Claim at position 23

-42. (canceled)

### Claim 43 (depends on 1)

A method of preventing or delaying the onset of an increase in glucose levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1.

### Claim at position 25

-46. (canceled)

### Claim 47 (depends on 1)

A method of modulating serum cholesterol levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1.

### Claim 48

(canceled)

### Claim 49 (depends on 1)

A method of modulating lipoprotein levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1.

### Claim 50

(canceled)

### Claim 51 (depends on 49)

The method of claim 49 wherein the lipoprotein is VLDL, HDL or LDL.

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54 (depends on 1)

A method of modulating serum triglyceride levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1.

### Claim 55

(canceled)

### Claim 56

(canceled)
